CD274 and digestive system neoplasm: In conclusion, gastrointestinal tumors, specifically the dMMR/MSI-H and TMB-H subtypes, benefit significantly from anti-PD-1/PD-L1 inhibitors, whereas the effectiveness of these inhibitors against the pMMR/MSS and low mutational load subtypes remains unclear.